Revolution Medicines (RVMD) Receives FDA’s “Safe to Proceed” Letter for Daraxonrasib
Key takeaways
- Revolution Medicines (RVMD) Receives FDA’s “Safe to Proceed” Letter for Daraxonrasib Noor Ul Ain Rehman Mon, May 11, 2026 at 6:14 AM GMT+7 2 min read RVMD Revolution Medicines, Inc.
- The company further stated that the EAP aims to offer treatment access in a monitored and controlled setting, consistent with FDA regulations governing investigational medicines.
- (NASDAQ:RVMD) is a clinical-stage precision oncology company that develops novel targeted therapies.
Revolution Medicines (RVMD) Receives FDA’s “Safe to Proceed” Letter for Daraxonrasib Noor Ul Ain Rehman Mon, May 11, 2026 at 6:14 AM GMT+7 2 min read RVMD Revolution Medicines, Inc. (NASDAQ:RVMD) is one of the best performing healthcare stocks so far in 2026. Revolution Medicines, Inc. (NASDAQ:RVMD) announced on May 1 that the U.S. Food and Drug Administration (FDA) issued a “safe to proceed” letter to the company, allowing the initiation of an expanded access treatment protocol (EAP) for daraxonrasib in patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC). Daraxonrasib is an investigational RAS(ON) inhibitor.
The company further stated that the EAP aims to offer treatment access in a monitored and controlled setting, consistent with FDA regulations governing investigational medicines. It added that the authorization marks a crucial step in the process of opening an EAP, and Revolution Medicines, Inc. (NASDAQ:RVMD) is “moving as quickly as possible” to ensure safe and equitable access to daraxonrasib for eligible patients in the United States. Management also stated that, as per FDA regulations governing expanded access programs, the company is unable to accept direct requests from caregivers or patients, and all requests for expanded access are required to be initiated by a licensed treating physician.
Revolution Medicines, Inc. (NASDAQ:RVMD) is a clinical-stage precision oncology company that develops novel targeted therapies. It discovers and develops cancer treatments through novel combination and monotherapy treatment regimens that enhance clinical benefits.